IGC Pharma, Inc. (IGC) Balance Sheet

The rapid erosion of cash reserves from $1.5 million in 2025Q2 to current levels indicates that the company's burn rate is significantly outpacing its ability to generate internal liquidity. This liquidity profile suggests that the firm is likely to face severe operational constraints unless it secures additional financing, which may come at a high cost to existing shareholders.

The consistent decline in total assets alongside a mounting deficit in retained earnings points to a business model that is currently eroding its capital base to fund clinical development. Investors should monitor whether this trajectory forces a pivot in strategy, as the current path appears unsustainable for a long-term clinical-stage entity.

The persistent expansion of the retained earnings deficit suggests that the company's core operations have yet to achieve a self-sustaining model. This ongoing erosion of equity may necessitate future dilutive equity offerings to maintain the company's status as a going concern, further impacting shareholder value.